Xenon Pharmaceuticals XENE Stock
Xenon Pharmaceuticals Price Chart
Xenon Pharmaceuticals XENE Financial and Trading Overview
| Xenon Pharmaceuticals stock price | 54.61 USD |
| Previous Close | 52.91 USD |
| Open | 52.91 USD |
| Bid | 39.64 USD x 200 |
| Ask | 67.84 USD x 200 |
| Day's Range | 52.91 - 55.59 USD |
| 52 Week Range | 30 - 63.95 USD |
| Volume | 1.79M USD |
| Avg. Volume | 1.14M USD |
| Market Cap | 5.3B USD |
| Beta (5Y Monthly) | 0.628 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.7 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 80.56 USD |
XENE Valuation Measures
| Enterprise Value | 4.03B USD |
| Trailing P/E | N/A |
| Forward P/E | -10.937482 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | |
| Price/Book (mrq) | 7.5354147 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -9.818 |
Trading Information
Xenon Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.628 |
| 52-Week Change | 68.02% |
| S&P500 52-Week Change | 24.48% |
| 52 Week High | 63.95 USD |
| 52 Week Low | 30 USD |
| 50-Day Moving Average | 55.1 USD |
| 200-Day Moving Average | 46.45 USD |
XENE Share Statistics
| Avg. Volume (3 month) | 1.14M USD |
| Avg. Daily Volume (10-Days) | 1.3M USD |
| Shares Outstanding | 96.67M |
| Float | 90.76M |
| Short Ratio | 3.39 |
| % Held by Insiders | 0.12% |
| % Held by Institutions | 111.02% |
| Shares Short | 4.04M |
| Short % of Float | 4.19% |
| Short % of Shares Outstanding | 4.17% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -24.21% |
| Return on Equity (ttm) | -37.53% |
Income Statement
| Revenue (ttm) | 0 USD |
| Revenue Per Share (ttm) | 0 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -328246016 USD |
| EBITDA | -410188992 USD |
| Net Income Avi to Common (ttm) | -383164992 USD |
| Diluted EPS (ttm) | -4.7 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.09B USD |
| Total Cash Per Share (mrq) | 11.33 USD |
| Total Debt (mrq) | 7.49M USD |
| Total Debt/Equity (mrq) | 0.56 USD |
| Current Ratio (mrq) | 27.794 |
| Book Value Per Share (mrq) | 7.271 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -306363008 USD |
| Levered Free Cash Flow (ttm) | -186274496 USD |
Profile of Xenon Pharmaceuticals
| Country | United States |
| State | BC |
| City | Burnaby |
| Address | 200-3650 Gilmore Way |
| ZIP | V5G 4W8 |
| Phone | 604 484 3300 |
| Website | https://www.xenon-pharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 358 |
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Q&A For Xenon Pharmaceuticals Stock
What is a current XENE stock price?
Xenon Pharmaceuticals XENE stock price today per share is 54.61 USD.
How to purchase Xenon Pharmaceuticals stock?
You can buy XENE shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Xenon Pharmaceuticals?
The stock symbol or ticker of Xenon Pharmaceuticals is XENE.
Which industry does the Xenon Pharmaceuticals company belong to?
The Xenon Pharmaceuticals industry is Biotechnology.
How many shares does Xenon Pharmaceuticals have in circulation?
The max supply of Xenon Pharmaceuticals shares is 96.67M.
What is Xenon Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Xenon Pharmaceuticals PE Ratio is now.
What was Xenon Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Xenon Pharmaceuticals EPS is -4.7 USD over the trailing 12 months.
Which sector does the Xenon Pharmaceuticals company belong to?
The Xenon Pharmaceuticals sector is Healthcare.
Xenon Pharmaceuticals XENE included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech Developed ex US SC NTR G
NQDMXUSSCGBPN
US
|
1704.47 GBP 2179.91 USD |
0
|
— — | 1704.47 GBP 2179.91 USD | 1704.47 GBP 2179.91 USD | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6185.56 USD — |
+0.85
|
— — | 6121.03 USD — | 6233.73 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
|
US Tech Global Market Composite
NQGM
US
|
2310.38 USD — |
-1.07
|
— — | 2287.99 USD — | 2333.46 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
31560.2 USD — |
-2.21
|
— — | 31469.2 USD — | 31924.72 USD — | — - | — — |
- {{ link.label }} {{link}}